Symbols / AVXL
AVXL Chart
About
Anavex Life Sciences Corp. operates as a biopharmaceutical company. It engages in developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, pain, and various types of cancer . Its lead drug candidate, ANAVEX 2-73 (blarcamesine), has completed a Phase 2a and a Phase 2b/3 clinical trial for Alzheimer's disease; a Phase 2 proof-of-concept study in Parkinson's disease dementia; and a Phase 2 and a Phase 3 study in adult patients and one Phase 2/3 study in pediatric patients with Rett syndrome. Its ANAVEX 2-73 is an orally available drug candidate designed to restore cellular homeostasis by targeting SIGMAR1 and muscarinic receptors. The ANAVEX 2-73 also exhibited anticonvulsant, anti-amnesic, neuroprotective, and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy. The company's ANAVEX 3-71, which targets SIGMAR1 and M1 muscarinic receptors, is a clinical stage drug candidate demonstrating disease-modifying activity against Alzheimer's disease in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid, and tau pathologies. Anavex Life Sciences Corp. was incorporated in 2004 and is headquartered in New York, New York.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 404.05M |
| Enterprise Value | 272.30M | Income | -39.95M | Sales | — |
| Book/sh | 1.37 | Cash/sh | 1.42 | Dividend Yield | — |
| Payout | 0.00% | Employees | 34 | IPO | — |
| P/E | — | Forward P/E | -31.14 | PEG | — |
| P/S | — | P/B | 3.19 | P/C | — |
| EV/EBITDA | — | EV/Sales | — | Quick Ratio | 20.81 |
| Current Ratio | 20.87 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -0.46 | EPS next Y | -0.14 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-05-11 | ROA | -21.56% |
| ROE | -33.63% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 92.67M |
| Shs Float | 89.78M | Short Float | 22.41% | Short Ratio | 12.47 |
| Short Interest | — | 52W High | 13.99 | 52W Low | 2.86 |
| Beta | 1.07 | Avg Volume | 1.96M | Volume | 999.22K |
| Target Price | $22.00 | Recom | Buy | Prev Close | $4.16 |
| Price | $4.36 | Change | 4.81% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$22.00
Mean price target
2. Current target
$4.36
Latest analyst target
3. DCF / Fair value
$-4.24
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$4.36
Low
$20.00
High
$24.00
Mean
$22.00
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-02-10 | reit | HC Wainwright & Co. | Buy → Buy | $20 |
| 2026-02-09 | main | D. Boral Capital | Buy → Buy | $24 |
| 2026-01-06 | main | D. Boral Capital | Buy → Buy | $24 |
| 2025-12-19 | main | D. Boral Capital | Buy → Buy | $24 |
| 2025-12-19 | reit | HC Wainwright & Co. | Buy → Buy | $20 |
| 2025-12-15 | main | D. Boral Capital | Buy → Buy | $24 |
| 2025-11-28 | reit | HC Wainwright & Co. | Buy → Buy | $20 |
| 2025-11-26 | main | D. Boral Capital | Buy → Buy | $24 |
| 2025-11-19 | main | HC Wainwright & Co. | Buy → Buy | $20 |
| 2025-11-14 | main | D. Boral Capital | Buy → Buy | $24 |
| 2025-10-29 | main | D. Boral Capital | Buy → Buy | $46 |
| 2025-10-24 | down | Jones Trading | Buy → Hold | — |
| 2025-10-07 | reit | HC Wainwright & Co. | Buy → Buy | $42 |
| 2025-10-02 | main | D. Boral Capital | Buy → Buy | $46 |
| 2025-10-01 | main | D. Boral Capital | Buy → Buy | $46 |
| 2025-09-10 | reit | HC Wainwright & Co. | Buy → Buy | $42 |
| 2025-09-10 | main | D. Boral Capital | Buy → Buy | $46 |
| 2025-08-27 | main | D. Boral Capital | Buy → Buy | $46 |
| 2025-08-22 | reit | HC Wainwright & Co. | Buy → Buy | $42 |
| 2025-08-13 | main | D. Boral Capital | Buy → Buy | $46 |
- CEO running 85 hospitals joins Alzheimer drug developer's board - Stock Titan Mon, 23 Feb 2026 12
- Is Anavex Life Sciences (AVXL) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance hu, 12 Feb 2026 08
- Anavex And Alzheimer's Disease: The Future Never Seems To Be Now - Seeking Alpha Fri, 30 Jan 2026 08
- Anavex Life Sciences Reports Fiscal 2025 Fourth Quarter Financial Results and Provides Business Update - Anavex Life Sciences ue, 25 Nov 2025 08
- ANAVEX LIFE SCIENCES ($AVXL) Releases Q1 2026 Earnings - Quiver Quantitative Mon, 09 Feb 2026 12
- Anavex Life Sciences Corp. (AVXL) Stock Analysis: Exploring a Potential 260% Upside in the Biotechnology Sector - DirectorsTalk Interviews Fri, 10 Oct 2025 07
- AVXL Stock Draws Retail Attention Ahead Of Company’s Meeting With EMA Committee - Stocktwits Mon, 10 Nov 2025 08
- Anavex stock plummets after negative CHMP vote on Alzheimer’s drug - Investing.com Fri, 14 Nov 2025 08
- Anavex Life Sciences (AVXL) Upgraded to Buy: Here's What You Should Know - Nasdaq hu, 12 Feb 2026 17
- Down 50.7% in 4 Weeks, Here's Why You Should You Buy the Dip in Anavex Life Sciences (AVXL) - Yahoo Finance ue, 02 Dec 2025 08
- Anavex Life Sciences (NASDAQ: AVXL) Quarter 2025 Reports $102.6M, Three-Year Runway - Stock Titan ue, 25 Nov 2025 08
- ANAVEX LIFE SCIENCES Earnings Preview: Recent $AVXL Insider Trading, Hedge Fund Activity, and More - Quiver Quantitative Sun, 23 Nov 2025 08
- Anavex: Negative EU Opinion Leaves Blarcamesine In Regulatory Purgatory (NASDAQ:AVXL) - Seeking Alpha ue, 10 Feb 2026 08
- Anavex Life Sciences (Nasdaq: AVXL) to Report Fiscal 2025 Results on Nov. 25 - Stock Titan ue, 18 Nov 2025 08
- FDA takes closer look at experimental Alzheimer’s pill in key meeting - Stock Titan ue, 06 Jan 2026 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 187500 | 945000 | — | Conversion of Exercise of derivative security at price 5.04 per share. | MISSLING CHRISTOPHER U | Chief Executive Officer | — | 2025-09-11 00:00:00 | D |
| 1 | 50000 | 88000 | — | Conversion of Exercise of derivative security at price 1.76 per share. | THOMAS STEFFEN PHD | Director | — | 2025-06-05 00:00:00 | D |
| 2 | 500000 | 460000 | — | Conversion of Exercise of derivative security at price 0.92 per share. | MISSLING CHRISTOPHER U | Chief Executive Officer | — | 2025-03-24 00:00:00 | D |
| 3 | 2835 | 10319 | — | Purchase at price 3.64 per share. | DONHAUSER PETER D.O. | Director | — | 2024-06-14 00:00:00 | D |
| 4 | 5000 | 22600 | — | Purchase at price 4.52 per share. | THOMAS STEFFEN PHD | Director | — | 2024-05-15 00:00:00 | D |
| 5 | 73380 | 374972 | — | Sale at price 5.11 per share. | MISSLING CHRISTOPHER U | Chief Executive Officer | — | 2024-03-28 00:00:00 | D |
| 6 | 73380 | 96862 | — | Conversion of Exercise of derivative security at price 1.32 per share. | MISSLING CHRISTOPHER U | Chief Executive Officer | — | 2024-03-28 00:00:00 | D |
Financials
| Line Item | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | -189.84K |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.21 |
| NormalizedEBITDA | -46.05M | -43.19M | -46.50M | -46.72M |
| TotalUnusualItems | -332.00K | 189.00K | -40.00K | -904.00K |
| TotalUnusualItemsExcludingGoodwill | -332.00K | 189.00K | -40.00K | -904.00K |
| NetIncomeFromContinuingOperationNetMinorityInterest | -46.38M | -43.00M | -47.51M | -47.98M |
| EBITDA | -46.38M | -43.00M | -46.54M | -47.62M |
| EBIT | -46.38M | -43.00M | -46.54M | -47.62M |
| NetInterestIncome | 4.68M | 7.32M | 5.55M | 947.00K |
| InterestExpense | 0.00 | 0.00 | 964.00K | 0.00 |
| InterestIncome | 4.68M | 7.32M | 6.52M | 947.00K |
| NormalizedIncome | -46.05M | -43.19M | -47.47M | -47.26M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -46.38M | -43.00M | -47.51M | -47.98M |
| TotalExpenses | 51.37M | 52.80M | 55.74M | 50.99M |
| TotalOperatingIncomeAsReported | -51.41M | -52.88M | -55.76M | -50.99M |
| DilutedAverageShares | 85.29M | 83.47M | 79.79M | 76.91M |
| BasicAverageShares | 85.29M | 83.47M | 79.79M | 76.91M |
| DilutedEPS | -0.54 | -0.52 | -0.60 | -0.62 |
| BasicEPS | -0.54 | -0.52 | -0.60 | -0.62 |
| DilutedNIAvailtoComStockholders | -46.38M | -43.00M | -47.51M | -47.98M |
| NetIncomeCommonStockholders | -46.38M | -43.00M | -47.51M | -47.98M |
| NetIncome | -46.38M | -43.00M | -47.51M | -47.98M |
| NetIncomeIncludingNoncontrollingInterests | -46.38M | -43.00M | -47.51M | -47.98M |
| NetIncomeContinuousOperations | -46.38M | -43.00M | -47.51M | -47.98M |
| TaxProvision | 0.00 | 7.00K | 358.00K | 268.00K |
| PretaxIncome | -46.38M | -43.00M | -47.51M | -47.62M |
| OtherIncomeExpense | 316.00K | 2.48M | 2.68M | 2.42M |
| OtherNonOperatingIncomeExpenses | 648.00K | 2.29M | 2.72M | 3.32M |
| GainOnSaleOfSecurity | -332.00K | 189.00K | -40.00K | -904.00K |
| NetNonOperatingInterestIncomeExpense | 4.68M | 7.32M | 5.55M | 947.00K |
| InterestExpenseNonOperating | 0.00 | 0.00 | 964.00K | 0.00 |
| InterestIncomeNonOperating | 4.68M | 7.32M | 6.52M | 947.00K |
| OperatingIncome | -51.37M | -52.80M | -55.74M | -50.99M |
| OperatingExpense | 51.37M | 52.80M | 55.74M | 50.99M |
| OtherOperatingExpenses | -37.00K | -75.00K | -25.00K | -54.00K |
| ResearchAndDevelopment | 37.59M | 41.84M | 43.72M | 37.92M |
| SellingGeneralAndAdministration | 13.82M | 11.04M | 12.05M | 13.07M |
| GeneralAndAdministrativeExpense | 13.82M | 11.04M | 12.05M | 13.07M |
| OtherGandA | 13.82M | 11.04M | 12.05M | 13.07M |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 |
|---|---|---|---|---|
| OrdinarySharesNumber | 86.67M | 84.80M | 82.07M | 77.94M |
| ShareIssued | 86.67M | 84.80M | 82.07M | 77.94M |
| TangibleBookValue | 94.87M | 120.26M | 141.85M | 142.49M |
| InvestedCapital | 94.87M | 120.26M | 141.85M | 142.49M |
| WorkingCapital | 94.87M | 120.26M | 141.85M | 142.49M |
| NetTangibleAssets | 94.87M | 120.26M | 141.85M | 142.49M |
| CommonStockEquity | 94.87M | 120.26M | 141.85M | 142.49M |
| TotalCapitalization | 94.87M | 120.26M | 141.85M | 142.49M |
| TotalEquityGrossMinorityInterest | 94.87M | 120.26M | 141.85M | 142.49M |
| StockholdersEquity | 94.87M | 120.26M | 141.85M | 142.49M |
| RetainedEarnings | -382.45M | -336.07M | -293.07M | -245.56M |
| AdditionalPaidInCapital | 477.23M | 456.25M | 434.84M | 387.98M |
| CapitalStock | 87.00K | 85.00K | 82.00K | 78.00K |
| CommonStock | 87.00K | 85.00K | 82.00K | 78.00K |
| PreferredStock | 0.00 | 0.00 | ||
| TotalLiabilitiesNetMinorityInterest | 8.95M | 15.30M | 12.53M | 10.21M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentLiabilities | 8.95M | 15.30M | 12.53M | 10.21M |
| CurrentDeferredLiabilities | 805.00K | 842.00K | 917.00K | 444.00K |
| CurrentDeferredRevenue | 805.00K | 842.00K | 917.00K | 444.00K |
| PensionandOtherPostRetirementBenefitPlansCurrent | 1.56M | 1.53M | 1.36M | 1.30M |
| PayablesAndAccruedExpenses | 6.58M | 12.94M | 10.26M | 8.47M |
| CurrentAccruedExpenses | 2.33M | 3.31M | 5.93M | 4.65M |
| Payables | 4.25M | 9.63M | 4.32M | 3.83M |
| AccountsPayable | 4.25M | 9.63M | 4.32M | 3.83M |
| TotalAssets | 103.81M | 135.57M | 154.39M | 152.71M |
| TotalNonCurrentAssets | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 103.81M | 135.57M | 154.39M | 152.71M |
| OtherCurrentAssets | 429.00K | 931.00K | 653.00K | 354.00K |
| CurrentDeferredAssets | 16.36K | |||
| PrepaidAssets | 354.16K | 371.91K | ||
| Receivables | 809.00K | 2.45M | 2.71M | 3.19M |
| TaxesReceivable | 809.00K | 2.45M | 2.71M | 3.19M |
| CashCashEquivalentsAndShortTermInvestments | 102.58M | 132.19M | 151.02M | 149.16M |
| CashAndCashEquivalents | 102.58M | 132.19M | 151.02M | 149.16M |
| Line Item | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 |
|---|---|---|---|---|
| FreeCashFlow | -39.04M | -30.81M | -27.79M | -24.24M |
| IssuanceOfCapitalStock | 9.20M | 11.28M | 27.88M | 20.98M |
| IncomeTaxPaidSupplementalData | 125.00K | 300.00K | 136.00K | 327.00K |
| EndCashPosition | 102.58M | 132.19M | 151.02M | 149.16M |
| BeginningCashPosition | 132.19M | 151.02M | 149.16M | 152.11M |
| ChangesInCash | -29.61M | -18.84M | 1.87M | -2.95M |
| FinancingCashFlow | 9.43M | 11.97M | 29.65M | 21.29M |
| CashFlowFromContinuingFinancingActivities | 9.43M | 11.97M | 29.65M | 21.29M |
| NetOtherFinancingCharges | -2.71M | -707.00K | -5.55M | |
| ProceedsFromStockOptionExercised | 2.94M | 691.00K | 1.78M | 1.01M |
| NetCommonStockIssuance | 9.20M | 11.28M | 27.88M | 20.98M |
| CommonStockIssuance | 9.20M | 11.28M | 27.88M | 20.98M |
| OperatingCashFlow | -39.04M | -30.81M | -27.79M | -24.24M |
| CashFlowFromContinuingOperatingActivities | -39.04M | -30.81M | -27.79M | -24.24M |
| ChangeInWorkingCapital | -4.22M | 2.75M | 2.50M | 5.36M |
| ChangeInOtherWorkingCapital | -37.00K | -75.00K | 473.00K | 444.00K |
| ChangeInPayablesAndAccruedExpense | -6.32M | 2.85M | 1.85M | -584.00K |
| ChangeInAccruedExpense | -943.00K | -2.46M | 1.35M | 330.00K |
| ChangeInPayable | -5.38M | 5.30M | 497.00K | -914.00K |
| ChangeInAccountPayable | -5.38M | 5.30M | 497.00K | -914.00K |
| ChangeInPrepaidAssets | 502.00K | -278.00K | -299.00K | 1.00K |
| ChangeInReceivables | 1.64M | 260.00K | 484.00K | 5.94M |
| OtherNonCashItems | 845.00K | |||
| StockBasedCompensation | 11.55M | 9.44M | 16.37M | 18.38M |
| NetIncomeFromContinuingOperations | -46.38M | -43.00M | -47.51M | -47.98M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for AVXL
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|